Richard Wieland has been appointed as a new member of the Company's Board of Directors effective January 1st 2017. Mr. Wieland will also serve as the interim Chief Financial Officer.
Mr. Wieland is a senior financial executive with a diversified Life Science business background with more than thirty-five years of business experience in both public and private companies. He completed over twenty capital transactions including two successful IPOs and eleven M&A transactions. Subsequent to the M&A transactions, he successfully managed the post-acquisition integration programs.